AMENDMENTS TO THE CLAIMS

1 (Currently Amended). A compound of the Formula I



Formula I

wherein:

R1 is NHR10, (substituted or unsubstituted C_1-C_6alkyl)NHR10 or (unsubstituted or substituted C_3-C_8 cycloalkyl)NHR10 wherein the substituted C_1-C_6 alkyl is substituted with one or more groups selected from: halo, hydroxyl, -OC_1-C_6 alkyl, cyano, SO_2(C_1-C_6 alkyl), OCF_3, CF_3, $CONH_2$, $CON(CH_3)_2$, or NO_2;

R10 is hydrogen, C_1-C_6alkyl, C_1-C_6alkyl(OH), C_1-C_6alkylidenyl(OH)R11, or an amino protecting group;

R11 is C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6alkyl(O)C_1-C_6alkyl, C(O)O-C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R2 is hydrogen, C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, unsubstituted or substituted C_3-C_8 cycloalkyl, unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, or indolinyl;

R4 is hydrogen, C_1-C_6alkyl, aryl, C_1-C_6alkylaryl, or C_2-C_6alkenyl;

R5 is hydrogen, aryl, C_1-C_6alkylaryl, hydroxy, C_1-C_6alkoxy, or unsubstituted or substituted C_1-C_6alkyl, wherein the substituted C_1-C_6 alkyl is substituted with one or more groups selected from: halo, hydroxyl, -OC_1-C_6 alkyl, cyano, SO_2(C_1-C_6 alkyl), OCF_3, CF_3, $CONH_2$, $CON(CH_3)_2$, or NO_2;

R6 and R7 are independently hydrogen, unsubstituted or substituted C_1-C_6alkyl, unsubstituted or substituted C_2-C_6alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated or a substituted C_3-C_8 cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C_1-C_6alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C_1-C_6alkyl)C_3-C_8cycloalkyl, or unsubstituted or substituted C_1-C_6alkylaryl;

R9 is hydrogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted –N-aryl, unsubstituted or substituted –S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2),-O-C_1-C_6alkyl, or C_1-C_6alkylaryl, wherein K1 is halo or $–CF_3$, and K2 is hydrogen, halo or $–CF_3$ or K1 and K2 together form a methylenedioxy group;

Q is $–S(O)_2$- or –C(O)-; and

m is a number selected from 1 or 2;

provided that R1 is (substituted C_1-C_6alkyl)NHR10 or (unsubstituted or substituted C_3-C_8 cycloalkyl)NHR10; or

R5 is hydroxy, C_1-C_6alkoxy, or substituted C_1-C_6alkyl; or

R6 and R7 are independently unsubstituted or substituted C_1-C_6alkyl or unsubstituted or substituted C_2-C_6alkenyl with the proviso that at least one group is substituted; or

R6 is hydrogen and R7 is substituted C_1-C_6alkyl or substituted C_2-C_6alkenyl; or

R6 and R7 together with the carbon atom to which they are attached form a substituted C_3-C_8 cycloalkyl group which is optionally partly unsaturated; or

R8 is substituted C_1-C_6alkyl, substituted aryl, unsubstituted or substituted (C_1-C_6alkyl)C_3-C_8cycloalkyl or substituted C_1-C_6alkylaryl;

or a pharmaceutically acceptable salt thereof

2 (Previously Presented) A compound according to claim 1 having Formula I



Formula I

wherein:

R1 is NHR10 or C_1-C_6alkylNHR10;

R10 is hydrogen, C_1-C_6alkyl, C_1-C_6alkyl(OH), C_1-C_6alkylidenyl(OH)R11, or an amino protecting group;

R11 is C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6alkyl(O)C_1-C_6alkyl, C(O)O-C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R2 is hydrogen, C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, unsubstituted or substituted C_3-C_8 cycloalkyl, unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, or indolinyl;

R4 is hydrogen, C_1-C_6alkyl, aryl, C_1-C_6alkylaryl, or C_2-C_6alkenyl;

R5 is hydroxy, C_1-C_6alkoxy, or substituted C_1-C_6alkyl;

R6 and R7 are independently hydrogen, C_1-C_6alkyl, or C_2-C_6alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated;

R8 is hydrogen, C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R9 is hydrogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted –N-aryl, unsubstituted or substituted –S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C_1-C_6alkyl, or C_1-C_6alkylaryl, wherein K1 is halo or –CF_3, and K2 is hydrogen, halo or –CF_3 or K1 and K2 together form a methylenedioxy group;

Q is –$S(O)_2$- or –C(O)-;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt thereof.

3 (Previously Presented). A compound according to claim 1 having Formula I



Formula I

wherein:

R1 is NHR10 or C_1-C_6alkylNHR10;

R10 is hydrogen, C_1-C_6alkyl, C_1-C_6alkyl(OH), C_1-C_6alkylidenyl(OH)R11, or an amino protecting group;

R11 is C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6alkyl(O)C_1-C_6alkyl, C(O)O-C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R2 is hydrogen, C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, unsubstituted or substituted C_3-C_8 cycloalkyl, unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, or indolinyl;

R4 is hydrogen, C_1-C_6alkyl, aryl, C_1-C_6alkylaryl, or C_2-C_6alkenyl;

R5 is hydrogen, aryl, C_1-C_6alkylaryl, hydroxy, C_1-C_6alkoxy, or unsubstituted or substituted C_1-C_6alkyl;

R6 and R7 are independently hydrogen, C_1-C_6alkyl, or C_2-C_6alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated;

R8 is substituted C_1-C_6alkyl, substituted aryl, unsubstituted or substituted (C_1-C_6alkyl)C_3-C_8cycloalkyl or substituted C_1-C_6alkylaryl;

R9 is hydrogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted –N-aryl, unsubstituted or substituted –S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C_1-C_6alkyl, or C_1-C_6alkylaryl, wherein K1 is halo or –CF_3, and K2 is hydrogen, halo or –CF_3 or K1 and K2 together form a methylenedioxy group;

Q is –$S(O)_2$- or –C(O)-;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt thereof.

4 (Previously Presented). A compound according to claim 1 having Formula I



Formula I

wherein:

R1 is NHR10 or C_1-C_6alkylNHR10;

R10 is hydrogen, C_1-C_6alkyl, C_1-C_6alkyl(OH), C_1-C_6alkylidenyl(OH)R11, or an amino protecting group;

R11 is C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6alkyl(O)C_1-C_6alkyl, C(O)O-C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R2 is hydrogen, C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, unsubstituted or substituted C_3-C_8 cycloalkyl, unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, or indolinyl;

R4 is hydrogen, C_1-C_6alkyl, aryl, C_1-C_6alkylaryl, or C_2-C_6alkenyl;

R5 is hydrogen, aryl, C_1-C_6alkylaryl, hydroxy, C_1-C_6alkoxy, or unsubstituted or substituted C_1-C_6alkyl;

R6 and R7 are independently unsubstituted or substituted C_1-C_6alkyl or unsubstituted or substituted C_2-C_6alkenyl with the proviso that at least one group is substituted; or

R6 is hydrogen and R7 is substituted C_1-C_6alkyl or substituted C_2-C_6alkenyl; or R6 and R7 together with the carbon atom to which they are attached form a substituted C_3-C_8 cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C_1-C_6alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C_1-C_6alkyl)C_3-C_8cycloalkyl or unsubstituted or substituted C_1-C_6alkylaryl;

R9 is hydrogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted –N-aryl, unsubstituted or substituted –S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C_1-C_6alkyl, or C_1-

C_6alkylaryl, wherein K1 is halo or $-CF_3$, and K2 is hydrogen, halo or $-CF_3$ or K1 and K2 together form a methylenedioxy group;

Q is $-S(O)_2-$ or $-C(O)-$;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt thereof.

5 (Previously Presented). A compound according to claim 1 having Formula I



Formula I

wherein:

R1 is (substituted C_1-C_6alkyl)NHR10 or (unsubstituted or substituted C_3-C_8 cycloalkyl)NHR10 wherein the substituted C_1-C_6 alkyl is substituted with one or more groups selected from: halo, hydroxyl, -OC_1-C_6 alkyl, cyano, SO_2(C_1-C_6 alkyl), OCF_3, CF_3, $CONH_2$, $CON(CH_3)_2$, or NO_2;

R10 is hydrogen, C_1-C_6alkyl, C_1-C_6alkyl(OH), C_1-C_6alkylidenyl(OH)R11, or an amino protecting group;

R11 is C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6alkyl(O)C_1-C_6alkyl, C(O)O-C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R2 is hydrogen, C_1-C_6alkyl, aryl, or C_1-C_6alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, unsubstituted or substituted C_3-C_8 cycloalkyl, unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, or indolinyl;

R4 is hydrogen, C_1-C_6alkyl, aryl, C_1-C_6alkylaryl, or C_2-C_6alkenyl;

R5 is hydrogen, aryl, C_1-C_6alkylaryl, hydroxy, C_1-C_6alkoxy, or unsubstituted or substituted C_1-C_6alkyl;

R6 and R7 are independently hydrogen, unsubstituted or substituted C_1-C_6alkyl, or unsubstituted or substituted C_2-C_6alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated or a substituted C_3-C_8 cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C_1-C_6alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C_1-C_6alkyl)C_3-C_8cycloalkyl or unsubstituted or substituted C_1-C_6alkylaryl;

R9 is hydrogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted –N-aryl, unsubstituted or substituted –S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C_1-C_6alkyl, or C_1-C_6alkylaryl, wherein K1 is halo or $–CF_3$, and K2 is hydrogen, halo or $–CF_3$ or K1 and K2 together form a methylenedioxy group;

Q is $–S(O)_2$- or –C(O)-;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt thereof.

6 (Previously Presented). A compound according to claim 2 wherein R1 is



or a pharmaceutically acceptable salt thereof.

7 (Previously Presented). A compound according to claim 6 wherein R6 and R7 are each C_1-C_3 alkyl or form a five or six membered carbocyclic ring; or a pharmaceutically acceptable salt or thereof.

8 (Previously Presented). A compound according to claim 7 wherein R5 is hydroxy, C_1-C_6alkoxy, C_1-C_6alkyl which is substituted by hydroxy or C_1-C_6alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

9 (Previously Presented). A compound according to claim 8 wherein R8 is hydrogen, methyl, ethyl or benzyl, or a pharmaceutically acceptable salt thereof.

10 (Previously Presented). A compound according to claim 3 wherein R1 is



or a pharmaceutically acceptable salt thereof.

11 (Previously Presented). A compound according to claim 10 wherein R6 and R7 are each C_1-C_3 alkyl or form a five or six membered carbocyclic ring, or a pharmaceutically acceptable salt thereof.

12 (Previously Presented). A compound according to claim 11 wherein R5 is hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkyl which is substituted by hydroxy or C_1-C_6alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

13 (Previously Presented). A compound according to claim 12 wherein R8 is C_1-C_6alkyl which is substituted by hydroxy or C_1-C_6alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

14 (Previously Presented). A compound according to claim 4 wherein R1 is



or a pharmaceutically acceptable salt thereof.

15 (Previously Presented). A compound according to claim 14 wherein R6 and R7 are independently C_1-C_6alkyl or C_2-C_6alkenyl, in which one or both groups are substituted by one, two, or three halo atoms; or R6 is hydrogen and R7 is C_1-C_6alkyl, C_2-C_6alkenyl which is substituted by one, two, or three halo atoms; or R6 and R7 together with the carbon atom to which they are attached may form a C_3-C_8cycloalkyl group which is

optionally partly unsaturated and which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

16 (Previously Presented). A compound according to claim 15 wherein R5 is hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkyl which is substituted by hydroxy or C_1-C_6alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

17 (Previously Presented). A compound according to claim 16 wherein R8 is hydrogen, C_1-C_6alkyl, (C_1-C_6alkyl)C_3-C_8cycloalkyl, benzyl, 1-phenylethyl, C_1-C_6alkyl which is substituted by hydroxy, methoxy, $CONH_2$, or $CON(CH_3)_2$, or C_1-C_6alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

18 (Previously Presented). A compound according to claim 5 wherein R1 is selected from $-C(CH_3)(CH_2OH)NH_2$, $-C(CH_2F)_2NH_2$, $-C(CH_2F)(CH_2CH_2F)NH_2$, $-C(CF_3)(CH_3)NH_2$, $-C(CH_2CH_2F)_2NH_2$, $-C(CH_2CH_3)(CH_2CF_3)NH_2$,







or a pharmaceutically acceptable salt thereof.

19 (Previously Presented). A compound according to claim 18 wherein R6 and R7 are each C_1-C_3 alkyl or form a five or six membered carbocyclic ring; or R6 and R7 are independently C_1-C_6alkyl or C_2-C_6alkenyl, in which one or both groups are substituted by one, two, or three halo atoms; or R6 is hydrogen and R7 is C_1-C_6alkyl, C_2-C_6alkenyl which is substituted by one, two, or three halo atoms; or R6 and R7 together with the carbon atom to which they are attached may form a C_3-C_8cycloalkyl group which is optionally partly unsaturated and which is substituted by one, two, or three halo atoms;
or a pharmaceutically acceptable salt thereof.

20 (Previously Presented). A compound according to claim 19 wherein R5 is hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkyl which is substituted by hydroxy or C_1-

C_6alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

21 (Previously Presented). A compound according to claim 20 wherein R8 is hydrogen, C_1-C_6alkyl, benzyl, C_1-C_6alkyl which is substituted by hydroxy, C_1-C_6alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

22 (Previously Presented). A compound according to claim 1 having Formula II



Formula II

wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 1 or a pharmaceutically acceptable salt thereof.

23 (Previously Presented). A compound according to claim 1 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl; or a pharmaceutically acceptable salt thereof.

24 (Previously Presented). A compound according to claim 23 wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C_1-C_6alkylaryl or unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C_1-C_6 alkyl, -

OC_1-C_6 alkyl, -OCF_3, amide, aryl, aryloxy, $SO_2(C_{1-6}$ alkyl), SO_2CF_3, NHamide, carboxamide, sulfonamide, NHsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

25 (Previously Presented). A compound according to claim 1 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C_1-C_6 alkylaryl group or an unsubstituted or substituted C_1-C_6alkyl(O)- C_1-C_6alkyl aryl group wherein:

the C_1-C_6alkyl moiety within the unsubstituted or substituted C_1-C_6 alkylaryl group is methyl, ethyl or propyl;

the C_1-C_6alkyl(O)- C_1-C_6alkyl moiety within the unsubstituted or substituted C_1-C_6alkyl(O)- C_1-C_6alkyl aryl group is a moiety of formula $–CH_2OCH_2$-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO_2Me, trifluoromethyl, and trifluoromethoxy
or a pharmaceutically acceptable salt thereof.

26 (Previously Presented). A compound according to claim 1 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C_1-C_6alkylaryl, C_1-C_6alkyl(O)-C_1-C_6alkylaryl, C_3-C_8 cycloalkyl, (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, indolyl, indolinyl, or (C_1-C_6 alkyl) indolyl.

27 (Previously Presented). A compound according to claim 1 wherein R4 is hydrogen or methyl, or a pharmaceutically acceptable salt thereof.

28 (Previously Presented). A compound according to claim 1 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, $CONH_2$, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

29 (Previously Presented). A compound of according to claim 28 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl;
or a pharmaceutically acceptable salt thereof.

30 (Previously Presented). A pharmaceutical formulation comprising one or more compounds according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable diluents or carriers therefor.

31 (Previously Presented). A pharmaceutical formulation according to claim 30 wherein the formulation further comprises one or more growth hormone secretagogue compounds and/or a bone-antiresorptive agent.

32 (Previously Presented). A process for producing a compound of Formula I as defined in claim 1 comprising coupling a compound of Formula XI or XIb



XI XI b

with a compound of formula XIII



XIII

wherein R1, R2, R3, R4, R5, R6, R7, R8 , R9 and Q are as defined in claim 1.

33 (Previously Presented). A process for producing a compound of Formula I as defined in claim 1 comprising deprotecting a compound of Formula



wherein R2, R3, R4, R5, R6, R7, R8 , R9, m and Q are as defined in claim 1, and PG is an amino protecting group.

34 (Previously Presented). A process for producing a compound of Formula I as defined in claim 1 comprising coupling a compound of Formula



with a compound of formula XIV

HOOC—R1

XIV

wherein R1, R2, R3, R4, R5, R6, R7, R8 , R9 and Q are as defined in claim 1.

35 and 36 (canceled).

37 (Previously Presented). A method of treating a physiological condition which is modulated or ameliorated by an increase in endogenous growth hormone comprising administering an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to an animal in need of said treatment.

38 (Previously Presented). A method of treating a condition selected from osteoporosis, physiological short stature caused by growth hormone deficiency, short stature associated with chronic illness, growth retardation associated with the Prader-Willi syndrome, intrauterine growth retardation, pulmonary dysfunction and ventricular dependency, insulin resistance, cachexia and protein loss due to cancer or AIDS comprising administering an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to an animal in need of said treatment.

39 (Previously Presented). A compound selected from the group consisting of

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[5-(4-chlorophenyl)-2-cyclopropylmethyl-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide;

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[5-(4-chlorophenyl)- 3,3-dimethyl-1,1-dioxo-2-(2-methoxyethyl)-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide;

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2-(2-fluoroethyl)-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide;

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2-(4,4,4-trifluorobutyl)-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide;

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[2-carbamoylmethyl-5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide; and

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-2-(N',N'-dimethylcarbamoyl)methyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide;
or a pharmaceutically acceptable salt thereof.

40 (Previously Presented). A compound of the formula



wherein
X is O, Y is 4-Cl, Z is H and R5 is CH_2CH_3; or a pharmaceutically acceptable salt thereof.

41 (Previously Presented). A method for the treatment of a physiological condition which is modulated or ameliorated by an increase in endogenous growth hormone comprising administering an effective amount of a compound of claim 39 or a pharmaceutically acceptable salt to an animal in need of said treatment.

42 (Previously Presented). A method for treating a condition selected from osteoporosis, physiological short stature caused by growth hormone deficiency, short stature associated with chronic illness, growth retardation associated with the Prader-Willi syndrome, intrauterine growth retardation, pulmonary dysfunction and ventricular dependency, insulin resistance, cachexia and protein loss due to cancer or AIDS comprising administering an effective amount of a compound of claim 39 or a pharmaceutically acceptable salt to an animal in need of said treatment.

43 (Currently Amended). A method for the treatment of a physiological condition which is modulated or ameliorated by an increase in endogenous growth hormone comprising administering an effective amount of a compound of claim 40 or a pharmaceutically acceptable salt to an animal in need of said treatment.

Deleted: c thereof

44 (Previously Presented). A method for treating a condition selected from osteoporosis, physiological short stature caused by growth hormone deficiency, short stature associated with chronic illness, growth retardation associated with the Prader-Willi syndrome, intrauterine growth retardation, pulmonary dysfunction and ventricular dependency, insulin resistance, cachexia and protein loss due to cancer or AIDS comprising administering an effective amount of a compound of claim 40 or a pharmaceutically acceptable salt to an animal in need of said treatment.

45 (Previously Presented). A compound according to claim 2 having Formula II



Formula II

wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 2 or a pharmaceutically acceptable salt thereof.

46 (Previously Presented). A compound according to claim 45 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, or unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl; wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C_1-C_6alkylaryl or unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C_1-C_6 alkyl, -OC_1-C_6 alkyl, -OCF_3, amide, aryl, aryloxy, SO_2(C_{1-6} alkyl), SO_2CF_3, NHamide, carboxamide, sulfonamide, NHsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

47 (Previously Presented). A compound according to claim 45 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C_1-C_6 alkylaryl group or an unsubstituted or substituted C_1-C_6alkyl(O)- C_1-C_6alkyl aryl group wherein:

the C_1-C_6alkyl moiety within the unsubstituted or substituted C_1-C_6 alkylaryl group is methyl, ethyl or propyl;

the C_1-C_6alkyl(O)- C_1-C_6alkyl moiety within the unsubstituted or substituted C_1-C_6alkyl(O)- C_1-C_6alkyl aryl group is a moiety of formula –CH_2OCH_2-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO_2Me, trifluoromethyl, and trifluoromethoxyor a pharmaceutically acceptable salt thereof.

48 (Previously Presented). A compound according to claim 45 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C_1-C_6alkylaryl, C_1-C_6alkyl(O)-C_1-C_6alkylaryl, C_3-C_8 cycloalkyl, (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, indolyl, indolinyl, and (C_1-C_6 alkyl) indolyl.

49 (Previously Presented). A compound according to claim 45 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, $CONH_2$, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

50 (Previously Presented). A compound of according to claim 49 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl;or a pharmaceutically acceptable salt thereof.

51 (Previously Presented). A compound according to claim 3 having Formula II



Formula II

wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 3 or a pharmaceutically acceptable salt thereof.

52 (Previously Presented). A compound according to claim 51 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, or unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl; wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C_1-C_6alkylaryl or unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C_1-C_6 alkyl, -OC_1-C_6 alkyl, -OCF_3, amide, aryl, aryloxy, SO_2(C_{1-6} alkyl), SO_2CF_3, NHamide, carboxamide, sulfonamide, NHsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

53 (Previously Presented). A compound according to claim 51 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C_1-C_6 alkylaryl group or an unsubstituted or substituted C_1-C_6alkyl(O)- C_1-C_6alkyl aryl group wherein:

the C_1-C_6alkyl moiety within the unsubstituted or substituted C_1-C_6 alkylaryl group is methyl, ethyl or propyl;

the C_1-C_6alkyl(O)- C_1-C_6alkyl moiety within the unsubstituted or substituted C_1-C_6alkyl(O)- C_1-C_6alkyl aryl group is a moiety of formula –CH_2OCH_2-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO_2Me, trifluoromethyl, and trifluoromethoxycyanophenyl, 4-cyanophenyl, 4-methanesulphonylphenyl, and 2-methyl thiazolyl;
or a pharmaceutically acceptable salt thereof.

54 (Previously Presented). A compound according to claim 51 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C_1-C_6alkylaryl, C_1-C_6alkyl(O)-C_1-C_6alkylaryl, C_3-C_8 cycloalkyl, (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, indolyl, indolinyl, or (C_1-C_6 alkyl) indolyl.

55 (Previously Presented). A compound according to claim 51 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, $CONH_2$, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

56 (Previously Presented). A compound of according to claim 55 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl;
or a pharmaceutically acceptable salt thereof.

57 (Previously Presented). A compound according to claim 4 having Formula II



Formula II

wherein
R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 4 or a pharmaceutically acceptable salt thereof.

58 (Previously Presented). A compound according to claim 57 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, or unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl; wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C_1-C_6alkylaryl or unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C_1-C_6 alkyl, -OC_1-C_6 alkyl, -OCF_3, amide, aryl, aryloxy, SO_2(C_{1-6} alkyl), SO_2CF_3, NHamide, carboxamide, sulfonamide, NHsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

59 (Previously Presented). A compound according to claim 57 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C_1-C_6 alkylaryl group or an unsubstituted or substituted C_1-C_6alkyl(O)- C_1-C_6alkyl aryl group wherein:

the C_1-C_6alkyl moiety within the unsubstituted or substituted C_1-C_6 alkylaryl group is methyl, ethyl or propyl;

the C_1-C_6alkyl(O)- C_1-C_6alkyl moiety within the unsubstituted or substituted C_1-C_6alkyl(O)- C_1-C_6alkyl aryl group is a moiety of formula –CH_2OCH_2-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO_2Me, trifluoromethyl, and trifluoromethoxy;
or a pharmaceutically acceptable salt thereof.

60 (Previously Presented). A compound according to claim 57 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C_1-C_6alkylaryl, C_1-C_6alkyl(O)-C_1-C_6alkylaryl, C_3-C_8 cycloalkyl, (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, indolyl, indolinyl, or (C_1-C_6 alkyl) indolyl.

61 (Previously Presented). A compound according to claim 57 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, $CONH_2$, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

62 (Previously Presented). A compound of according to claim 61 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl;
or a pharmaceutically acceptable salt thereof.

63 (Previously Presented). A compound according to claim 5 having Formula II



Formula II

wherein
R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 5 or a pharmaceutically acceptable salt thereof.

64 (Previously Presented). A compound according to claim 63 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, or unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl; wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C_1-C_6alkylaryl or unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C_1-C_6 alkyl, -OC_1-C_6 alkyl, -OCF_3, amide, aryl, aryloxy, SO_2(C_{1-6} alkyl), SO_2CF_3, NHamide, carboxamide, sulfonamide, NHsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

65 (Previously Presented). A compound according to claim 63 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C_1-C_6 alkylaryl group or an unsubstituted or substituted C_1-C_6alkyl(O)- C_1-C_6alkyl aryl group wherein:

the C_1-C_6alkyl moiety within the unsubstituted or substituted C_1-C_6 alkylaryl group is methyl, ethyl or propyl;

the C_1-C_6alkyl(O)- C_1-C_6alkyl moiety within the unsubstituted or substituted C_1-C_6alkyl(O)- C_1-C_6alkyl aryl group is a moiety of formula –CH_2OCH_2-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO_2Me, trifluoromethyl, and trifluoromethoxy;
or a pharmaceutically acceptable salt thereof.

66 (Previously Presented). A compound according to claim 63 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C_1-C_6alkylaryl, C_1-C_6alkyl(O)-C_1-C_6alkylaryl, C_3-C_8 cycloalkyl, (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, indolyl, indolinyl, or (C_1-C_6 alkyl) indolyl.

67 (Previously Presented). A compound according to claim 63 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, $CONH_2$, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

68 (Previously Presented). A compound of according to claim 63 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl;
or a pharmaceutically acceptable salt thereof.

69 (Previously Presented). A compound according to claim 21 having Formula II



Formula II

wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 21 or a pharmaceutically acceptable salt thereof.

70 (Previously Presented). A compound according to claim 69 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C_1-C_6alkylaryl, unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl, or unsubstituted or substituted (C_1-C_6 alkyl) C_3-C_8 cycloalkyl; wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C_1-C_6alkylaryl or unsubstituted or substituted C_1-C_6alkyl(O)-C_1-C_6alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C_1-C_6 alkyl, -OC_1-C_6 alkyl, -OCF_3, amide, aryl, aryloxy, SO_2(C_{1-6} alkyl), SO_2CF_3, NHamide, carboxamide, sulfonamide, NHsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

71 (Previously Presented). A compound according to claim 69 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C_1-C_6 alkylaryl group or an unsubstituted or substituted C_1-C_6alkyl(O)- C_1-C_6alkyl aryl group wherein:

the C_1-C_6alkyl moiety within the unsubstituted or substituted C_1-C_6 alkylaryl group is methyl, ethyl or propyl;

the C_1-C_6alkyl(O)- C_1-C_6alkyl moiety within the unsubstituted or substituted C_1-C_6alkyl(O)- C_1-C_6alkyl aryl group is a moiety of formula –CH_2OCH_2-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO_2Me, trifluoromethyl, and trifluoromethoxy;

or a pharmaceutically acceptable salt thereof.

72 (Previously Presented). A compound according to claim 69 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C_1-C_6alkylaryl, C_1-C_6alkyl(O)-C_1-C_6alkylaryl, C_3-C_8 cycloalkyl, (C_1-C_6 alkyl) C_3-C_8 cycloalkyl, indolyl, indolinyl, or (C_1-C_6 alkyl) indolyl.

73 (Previously Presented). A compound according to claim 69 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, $CONH_2$, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

74 (Previously Presented). A compound of according to claim 69 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl;
or a pharmaceutically acceptable salt thereof.